MarketPulse

A1C reduction

2 articles
BenzingaBenzinga··Vandana Singh

Eli Lilly Phases Out Select European Insulin Products by 2027

Eli Lilly discontinuing select insulin products across EU/EEA by Q2 2027 due to commercial factors. Company's experimental retatrutide shows strong diabetes and weight-loss results.
LLYweight lossEurope
BenzingaBenzinga··Vandana Singh

Eli Lilly's Diabetes Drug Delivers 17% Weight Loss, But Analysts Question Valuation

Eli Lilly's retatrutide shows strong weight loss results in trials, but HSBC downgrades stock citing overvaluation concerns.
LLYclinical trialweight loss